Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells
AssigneeNantKwest, Inc.
InventorsHans G. Klingemann, Laurent H. Boissel, Abhijit Dandapat
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions of NK-92™ cells that express a combination of PD-L1 CAR, CD16 and IL2, and the method of using these cells to reduce tumor cells and cells in tumor microenvironment (e.g., MDSCs or TAMs) and treat cancer.
Claims9
A natural killer (NK)-92 cell having American Type Culture Collection (ATCC) deposit number CRL-2407 transfected to express a protein encoded by a recombinant construct comprising a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:11 to thereby effect expression of an anti-programmed death-ligand 1 (PD-L1) chimeric antigen receptor (CAR), an endoplasmic reticulum interleukin-2 (erIL-2) and a fragment crystallizable (Fc) receptor, wherein the PD-L1 CAR comprises anti PD-L1 scFv, CD8 Hinge, CD28 transmembrane domain, and FcεRIγ signaling domain, and wherein the Fc receptor is CD16.
A recombinant construct comprising a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:
- 11.
A NK-92 cell having ATCC deposit no. CRL-2407, transfected with a recombinant construct having nucleotides 1552-4681 of SEQ ID NO:11, that encodes for a PD-L1 CAR, an erIL-2, and a Fc receptor, wherein the PD-L1 CAR comprises anti PD-L1 scFv, CD8 Hinge, CD28 transmembrane domain, and FcεRIγ signaling domain, and wherein the Fc receptor is CD16.
A NK-92 cell having ATCC deposit no. CRL-2407, and expressing from a recombinant construct comprising a nucleic acid molecule a PD-L1 CAR having at least 90% sequence identity to amino acids 1-272 of SEQ ID NO:12, an erIL-2 having at least 90% sequence identity to SEQ ID NO:13, and a Fc receptor having at least 90% identity to amino acids 428-681 of SEQ ID NO:12, wherein the PD-L1 CAR comprises anti PD-L1 scFv, CD8 Hinge, CD28 transmembrane domain, and FcεRIγ signaling domain, and wherein the Fe receptor is CD16, and wherein direct cytotoxicity of the NK-92 cell on PD-LI-expressing cells is 40-100% when the effector to target ratio is 10.
Dependencies are inferred from the claim text.